drugset / Trial / NCT06185400
RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations
Phase 2
Not yet recruiting
108 enrolled
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Disitamab Vedotin（RC48）combined with EGFR or HER2 TKIs in locally advanced or metastatic NSCLC Patients with HER2 Alterations.
Timeline
- Start
- 2024-02-01
- Primary completion
- 2025-07-01
- Completion
- 2026-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Almonertinib | Small molecule | — | — |
| Subject | Disitamab Vedotin | Monoclonal antibody | — | — |
| Subject | Firmonertinib | Small molecule | — | — |
| Subject | Osimertinib | Small molecule | — | — |
| Subject | Pyrotinib | Small molecule | — | — |